RESI @ TMCx Big Pharma Panel Announcement

21 May

By Natasha Eldridge, Marketing Manager, Life Science Nation

natashaPanelists will discuss in-depth the key motivators behind big pharma’s shift towards an early stage strategy as a way to fill the gaps in their pipelines. What indication areas are the most sought after? How does an early stage entrepreneur interface with business development executives from pharmaceutical companies? LSN’s Big Pharma RESI Panelists will shed light on these questions and more.

Moderated by Donnie McGrath, VP, Business Development, Bristol-Myers Squibb this panel will feature:

Mark Ralph, Director, External Partnership Operations,Boehringer Ingelheim

Melinda Richter, Head, Johnson & Johnson Innovation, JLABS

Michael Martin, Senior Investment Director, Takeda Ventures, Inc.

Sylvaine Cases, Head of External Science & Partnering, US West, Sanofi

Hear from big pharma executives as they explain how they engage with early stage startups, and how they like to be contacted. The speakers will help the audience understand their timeline for contact, and give advice on how to create a dialogue that leads to a relationship and an eventual alliance. If you need to understand the timeframe and limitations of how big pharma corporate works, this expert session is crucial for you to attend.

resi5-24final-800-300v2

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: